Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered-Reference-Cited by-同舟云学术

Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered

Published:2024-06-27 Issue:1 Volume:12 Page:
ISSN:2051-5960
Container-title:Acta Neuropathologica Communications
language:en
Short-container-title:acta neuropathol commun

Author:

Tauziède-Espariat Arnault,Castel David,Ajlil Yassine,Auffret Lucie,Appay Romain,Mariet Cassandra,Hasty Lauren,Métais Alice,Chrétien Fabrice,Grill Jacques,Varlet Pascale

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s40478-024-01818-8.pdf

Reference14 articles.

1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021;noab106.

2. Auffret L, Ajlil Y, Tauziède-Espariat A, Kergrohen T, Puiseux C, Riffaud L et al (2023) A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation. Acta Neuropathol (Berl) 147:2

3. Roberts HJ, Ji S, Picca A, Sanson M, Garcia M, Snuderl M et al (2023) Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations. Acta Neuropathol (Berl) 146:849–852

4. Fujii Y, Hatae R, Hata N, Suzuki SO, Sangatsuda Y, Takigawa K et al (2022) A case of ganglioglioma grade 3 with H3 K27M mutation arising in the medial temporal lobe in an elderly patient. Neuropathol off J Jpn Soc Neuropathol 42:197–203

5. Zanello M, Pages M, Tauziède-Espariat A, Saffroy R, Puget S, Lacroix L et al (2016) Clinical, imaging, histopathological and molecular characterization of Anaplastic Ganglioglioma. J Neuropathol Exp Neurol 75:971–980